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Polymer and Gold Anchor markers show high and sharp 
contrast with less artifact for most imaging system but can 
not be used with an As500 MV imaging system. Although we 
need to adjust our IGRT protocol, they present the best 
characteristics for our practice. Furthermore, we reduced 
inter observer variability. 
Standard deviation vector of registration is 1.9 mm on bones 
matching and 0.1 mm on markers matching. 
 
 
 
Conclusions: Choice of fiducial markers depends on IGRT 
systems and protocols we use. It might be necessary to adopt 
new IGRT procedures.  
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Futhermore, fiducial markers registration clearly increase 
accuracy of treatment and reduce inter-operator variability. 
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Purpose/Objective: To test the Calypso radiofrequency in its 
accuracy and reliability in prostate matching, in comparison 
to cone beam CT imaging. To use Calypso's tracking system in 
order to account for prostate motion, in preparation for 
future prostate SBRT treatments. To use Calypso in place of 
daily kv-kv imaging. 
Materials and Methods: Two patients have been treated thus 
far, using our new Calypso system. They were treated with 
IMRT arc therapy, to a standard total dose of 76.2Gy, 2.31Gy 
per Fraction. Prior to treatment planning, the patients were 
selected to be implanted with 3 Calypso transponders, with 
the same criteria of Goldmarker implementation, with the 
added limitation that the abdomen may not be more than 
17cm from the prostate. The Calypso system can monitor 
patient motion in three dimensions. At the Calypso tracking 
station, prostate motion tolerances were set to 0.5cm in all 
directions except in the anterior direction, which was limited 
to 0.3cm in order to avoid rectal irradiation. Should the 
prostate position exceed the set limits, then the beam would 
be automatically held. For treatment, the patients were 
aligned on the treatment table to their tattoos, and the 
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Calypso console was used to shift the patient to the exact 
Isocenter position. The following imaging protocol was 
followed; Day 1-3 CBCT, or until 3 consecutive CBCTs showed 
acceptable bladder fullness and an empty rectum, afterwards 
only 1 CBCT per week. Following a CBCT we would manually 
match the transponders and apply any necessary shifts. The 
discrepancy between the CBCT and the Calypso shifts was 
then noted. We also recorded maximum prostate motion 
shown on the Calypso tracking station during the treatment, 
as well as the time that the beam was held due to prostate 
motion outside of set tolerances.  
Results: The average discrepancy between the Calypso 
transponder match and CBCT in the lateral direction was -
0.09±0.46mm, longitudinal 0.81±0.66mm, and vertical -
0.69±0.68mm. The average prostate motion during irradiation 
was 0.44±0.82mm in the lateral direction, 0.3±1.4mm in the 
longitudinal, and 0.4±2.0mm in the vertical direction. The 
maximum prostate motion recorded was 0.64cm in the 
vertical direction, and was the result of the patient coughing 
during treatment. In this case the beam was held for 120 
seconds, and the patient had to be shifted back to the 
Isocenter. On one other occasion, the beam was held for 5 
seconds before the prostate moved back within tolerance.  
Conclusions: Based on the positioning accuracy that we have 
seen from the Calypso system, we will soon begin to treat 
prostate patients using the SBRT technique. So far, prostate 
motion has been seen to be quite stable during treatment, 
with the largest prostate motion occurring in the vertical 
direction. Our preparations will help us in setting prostate 
SBRT motion tolerances. We will continue to use Calypso for 
positioning and tracking prostate motion. 
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Purpose/Objective: SRS is becoming a standard treatment in 
many departments. However conventional external beam 
treatments such as VMAT are able to deliver similar 
treatments especially for oligometastatic disease to the 
brain. We performed a prospective trial on 10 patients being 
treated for melanoma brain metastases comparing BrainLab’s 
Exactrac Imaging and CBCT, focusing on efficacy, accuracy 
and economic factors. 
Materials and Methods: 10 cases of SRS planned for single 
fraction treatment on a Varian Unique Linear Accelerator 
using the BrainLab Exactrac Imaging System and 6D robotic 
couch were replanned for VMAT treatment on a Varian 21IX 
Linear Accelerator using CBCT imaging on a standard couch. 
Planning and treatment time, imaging accuracy and economic 
factors were assessed. 
Results: Planning time for SRS using BrainLab's iPlan for 
treatment on the Varian Unique machine could take 
anywhere from 3 hours to several days depending on the 
number of metastases, while VMAT planning took less on 
average, around 4 hours regardless of the number of 
metastases. Treatment time using Exactrac Imaging ranged 
from 20 to 45 minutes, with longer treatment times needed 
for patients with multiple metastases. With VMAT, treatment 
times were more consistent with almost all cases taking 30 
minutes to treat regardless of the number of metastases. 
Although treatment time was much quicker, the time to 
acquire the CBCT was longer compared to Exactrac Imaging. 
Accuracy of less than 0.5mm in six planes was achieved on 
BrainLab’s robotic couch which was much better than the 
1mm tolerance on a standard couch for VMAT. 
Conclusions: Comparing iPlan to VMAT, planning times are 
similar unless multiple metastases are being planned in which 
case VMAT is much quicker. Treatment and imaging times are 
similar, however VMAT treatment times were more consistent 
regardless of the number of metastases being treated, this in 
particular is clinically important for work flow of the 
department. The imaging tolerances of CBCT are less 
accurate than Exactrac Imaging and this should be taken into 
account when considering the use of CBCT for SRS brain 
treatments. In our cases corrections could only be accounted 
for x, y and z planes rather than 6 planes which BrainLab’s 
robotic couch offers. The accuracy of Exactrac Imaging, while 
beneficial, may not necessarily be needed for SRS treatments 
of oligometastatic disease to the brain. The use of CBCT for 
imaging is still an efficient and economical substitute for 
radiation therapy centres who do not have access to Exactrac 
Imaging. However it is important that doses are assessed with 
regard to imaging tolerances. 
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Purpose/Objective: Overall survival for lung cancer patients 
is poor partly due to local recurrence. The local control rate 
may be improved by increasing the dose. However, if the 
anatomy of the patient changes during RT these high doses 
can shift into the oesophagus and other mediastinal organs 
increasing the risk of severe toxicity. 
The aim of this study is to identify how much the oesophagus 
moves during the RT course and the impact on the dose 
distribution. 
Materials and Methods: Twenty consecutive lung cancer 
patients treated with chemo-RT were included in this study. 
All patients had a 4D planning-CT scan (p-CT) and two 
additional 4DCT control scans (c-CT) at fraction 10 and 20. 
The patients were treated with a homogeneous dose 
distribution to the target. The maximum dose to the 
oesophagus was equal to the prescribed dose allowing for a 
higher dose to maximum 1 cm3of the oesophagus. For each 
patient, an experienced radiographer contoured the 
oesophagus in two different structures based on the 
recommendations of the Danish Lung Cancer Group. First, the 
full extent of the oesophagus (oes) was contoured, and then 
the oesophagus was contoured in the extent of the tumour 
(oes-T). In the Eclipse registration module, a rigid 6D tumour 
match between the p-CT and each of the c-CT scans was 
performed and the shift of the oesophagus was obtained for 
the segments oes and oes-T. The treatment plan was copied 
to the c-CTs using the 6D registration and the dose was re-
